Breast cancer and hormone replacement therapy: Putting the risk into perspective

Gynecological Endocrinology

Volumn 15, Issue SUPPL. 6, 2001, Pages 53-60

  Campagnoli, C ^a,c   Abba C ^a   Ambroggio, S ^a   Biglia, N ^b   Ponzone, R ^b  

^a S ANNA HOSPITAL   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

^c NONE   (Italy)

Author keywords

Body weight; Breast cancer; Estrogen replacement therapy; Hormone peplacement therapy; Insulin like growth factor I; Progestins; Sex hormone binding globulin

Indexed keywords

ESTROGEN; GESTAGEN;

BREAST TUMOR; ESTROGEN THERAPY; FEMALE; HUMAN; OBESITY; REVIEW; RISK FACTOR;

BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; OBESITY; PROGESTINS; RISK FACTORS;

EID: 0345132371     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/gye.15.s6.53.60     Document Type: Review

References (46)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative re-analysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-59
2. Magnusson C, Baron JA, Correia N, et al. Breast-cancer risk following long-term oestrogen-progestin-replacement therapy. Int J Cancer 1999; 81:339-44
3. Persson I, Weiderpass E, Bergkvist L, et al. Risk of breast and endometrial cancer after estrogen-progestin replacement. Cancer Causes Control 1999;10:253-60
4. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J Am Med Assoc 2000;26:283-91
5. Ross RK, Paganini-Hill A, Wan PC, et al. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-32
6. Campagnoli C, Ambroggio S, Biglia N, et al. Conjugated estrogens and breast cancer risk. Gynecol Endocrinol 1999;12(Suppl 6):13-19
7. Laidlaw IJ, Clarke RB, Howell A, et al. The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology 1995;136: 164-71
8. Pasqualini JR, Chetrite G, Blacker C, et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer. J Clin Endocrinol Metab 1996;81:1460-4
9. Poortman J, Thijssen JHH, De Waard F. Plasma oestrone, estradiol and androstenedione levels in post-menopausal women: relation to body weight and height. Maturitas 1981;3:65-71
10. Campagnoli C, Biglia N, Cantamessa C, et al. HRT and breast cancer risk: a clue for interpreting the available data. Maturitas 1999;33:185-90
11. Kaaks R. Nutrition, hormones, and breast cancer: is insulin the missing link? Cancer Causes Control 1996;7:605-11
12. Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colonrectal cancer risk in women. J Natl Cancer Inst 2000;92: 1592-600
13. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351: 1393-6
14. Toniolo P, Bruning PF, Akhmedkhanov A, et al. Serum insulin-like growth factor-I and breast cancer risk. Int J Cancer 2000;88:828-32
15. Nachtigall EE. Sex hormone-binding globulin and breast cancer risk. Prim Care Update Obstet Gynecol 1999;6:39-43
16. Westley BR, May FEB. Role of insulin-like growth factors in steroid modulated proliferation. J Steroid Biochem Molec Biol 1994;51:1-9
17. Fortunati N, Becchis M, Catalano MG, et al. Sex hormone-binding globulin, its membrane receptors, and breast cancer: a new approach to the modulation of estradiol action in neoplastic cells. J Steroid Biochem Mol Biol 1999;69:473-9
18. Campagnoli C, Biglia N, Peris C, et al. Potential impact on breast cancer risk of circulating insulin-like growth factor-I modifications induced by oral HRT in menopause. Gynecol Endocrinol 1995;9:67-74
19. Pollak M. IGF-I physiology and breast cancer. Rec Results Cancer Res 1998;152:63-6
20. Decensi A, Bonanni B, Guerieri-Gonzaga A, et al. Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 1998;90:1461-5
21. Campagnoli C, Ambroggio S, Biglia N, et al. Insulin-like growth factor-I and the risk of breast cancer [Letter]. Lancet 1998;352:488-9
22. Carmina E, Lo Dico G, Carollo F, et al. Serum IGF-I and binding proteins 1 and 3 in postmenopausal women and the effects of estrogen. Menopause 1996;3:85-9
23. Helle SI, Omsjo IH, Cwyfan-Hughes SC, et al. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin Endocrinol 1996;45:727-32
24. Heald A, Selby PL, White A, et al. Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis. Am J Obstet Gynecol 2000; 183:593-600
25. Kam GYW, Leung KC, Baxter RC, et al. Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J Clin Endocrinol Metab 2000;85:1918-22
26. Bellantoni MF, Vittone J, Campfield AT, et al. Effects of oral vs transdermal estrogen on the growth hormone/insulin-like growth factor-I axis in younger and older postmenopausal women: a clinical research center study. J Clin Endocrinol Metab 1996;81:2848-53
27. Grodstein F, Martinez ME, Platz EA, et al. Post-menopausal hormone use and risk for colonrectal cancer and adenoma. Ann Intern Med 1998;128: 705-9
28. Andersson B, Mattsson LA, Hahn L, et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:638-43
29. Newcomb PA, Longnecker MP, Storer BE, et al. Long-term hormone replacement therapy and risk of breast cancer in post-menopausal women. Am J Epidemiol 1995;142:788-95
30. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93
31. Stanford J, Weiss N, Voigt L, et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. J Am Med Assoc 1995;274: 137-42
32. Willett WC, Colditz G, Stampfer M. Postmenopausal estrogen - opposed, unopposed, or none of the above. J Am Med Assoc 2000;26:534-5
33. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormone on breast cancer risk in Denmark. Int J Cancer 1988;42:832-8
34. Persson I, Yuen J, Bergkvist L, et al. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327-32
35. Persson I, Thurriel E, Bergström R, et al. Hormone replacement therapy and the risk of breast cancer: nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer 1997;72:758-61
36. Magnusson C, Persson I, Adami HO. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin [Letter]. J Natl Cancer Inst 2000;14:1183-4
37. Miller VT, Muesing RA, LaRosa JC, et al. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoproteins A-1. Obstet Gynecol 1991;77:235-40
38. Campagnoli C, Biglia N, Cantamessa C, et al. Effects of progestins on IGF-I serum level in estrogen-treated postmenopausal women. Zentralbl Gynäkol 1997;119:7-11
39. Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963-8
40. Schindler AE, Campagnoli C, Druckmann R, et al. Aspects of progestin activity on the breast. Maturitas 1998;29:61-5
41. Speroff L. Postmenopausal estrogen-progestin therapy and breast cancer: a clinical response to epidemiological reports. Climacteric 2000;3:3-12
42. Mor G, Yue W, Santen RJ, et al. Macrophages, estrogen, and the microenvironment of breast cancer. J Steroid Biochem Mol Biol 1998;5:403-11
43. Mor G, Kohen F, Garcia-Velasco J, et al. Regulation of Fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 2000;73:185-94
44. Kuller LH. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin [Letter]. J Natl Cancer Inst 2000;13:1100
45. Ross RK, Paganini-Hill A, Roy S, et al. Past and present preferred prescribing practices of hormone replacement therapy among Los Angeles gynecologists: possible implications for public health. Am J Public Health 1998;78:516-19
46. Gambrell RD, Maier RC, Sanders BI. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 1983; 62:435-43